Similar articles

• [Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the German Hodgkin Study Group].

  Frerker B, Hildebrandt G. Frerker B, et al. Strahlenther Onkol. 2020 May;196(5):488-491. doi: 10.1007/s00066-020-01600-4. Strahlenther Onkol. 2020. PMID: 32170351 German. No abstract available.
• Controversies in the treatment of early-stage Hodgkin's lymphoma.

  Longo DL, Armitage JO. Longo DL, et al. N Engl J Med. 2015 Apr 23;372(17):1667-9. doi: 10.1056/NEJMe1502888. N Engl J Med. 2015. PMID: 25901431 No abstract available.
• Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.

  Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, Luminari S, Polimeno G, Federico M. Gobbi PG, et al. Hematol Oncol. 2012 Dec;30(4):194-9. doi: 10.1002/hon.1024. Epub 2012 Jan 23. Hematol Oncol. 2012. PMID: 22271092
• Clinicopathologic and molecular features of Hodgkin's lymphoma.

  Younes A, Carbone A. Younes A, et al. Cancer Biol Ther. 2003 Sep-Oct;2(5):500-7. doi: 10.4161/cbt.2.5.510. Cancer Biol Ther. 2003. PMID: 14614314 Review.
• Therapeutic recommendations for early stage Hodgkin lymphomas.

  Depaus J, Delcourt A, André M. Depaus J, et al. Br J Haematol. 2019 Jan;184(1):9-16. doi: 10.1111/bjh.15623. Epub 2018 Nov 28. Br J Haematol. 2019. PMID: 30485401 Review.